Top

Published in:

01-12-2016 | Original Article

Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment

Authors: D. Ovejero, Y. H. Lim, A. M. Boyce, R. I. Gafni, E. McCarthy, T. A. Nguyen, L. F. Eichenfield, C. M. C. DeKlotz, L. C. Guthrie, L. L. Tosi, P. S. Thornton, K. A. Choate, M. T. Collins

Published in: Osteoporosis International | Issue 12/2016

Abstract

Summary

Cutaneous skeletal hypophosphatemia syndrome (CSHS), caused by somatic RAS mutations, features excess fibroblast growth factor-23 (FGF23) and skeletal dysplasia. Records from 56 individuals were reviewed and demonstrated fractures, scoliosis, and non-congenital hypophosphatemia that in some cases were resolved. Phosphate and calcitriol, but not skin lesion removal, were effective at controlling hypophosphatemia. No skeletal malignancies were found.

Purpose

CSHS is a disorder defined by the association of epidermal and/or melanocytic nevi, a mosaic skeletal dysplasia, and an FGF23-mediated hypophosphatemia. To date, somatic RAS mutations have been identified in all patients whose affected tissue has undergone DNA sequencing. However, the clinical spectrum and treatment are poorly defined in CSHS. The purpose of this study is to determine the spectrum of the phenotype, natural history of the disease, and response to treatment of hypophosphatemia.

Methods

Five CSHS subjects underwent prospective data collection at clinical research centers. A review of the literature identified 45 reports that included a total of 51 additional patients, in whom the findings were compatible with CSHS. Data on nevi subtypes, bone histology, mineral and skeletal disorders, abnormalities in other tissues, and response to treatment of hypophosphatemia were analyzed.

Results

Fractures, limb deformities, and scoliosis affected most CSHS subjects. Hypophosphatemia was not present at birth. Histology revealed severe osteomalacia but no other abnormalities. Skeletal dysplasia was reported in all anatomical compartments, though less frequently in the spine; there was no clear correlation between the location of nevi and the skeletal lesions. Phosphate and calcitriol supplementation was the most effective therapy for rickets. Convincing data that nevi removal improved blood phosphate levels was lacking. An age-dependent improvement in mineral abnormalities was observed. A spectrum of extra-osseous/extra-cutaneous manifestations that included both benign and malignant neoplasms was present in many subjects, though osteosarcoma remains unreported.

Conclusion

An understanding of the spectrum, natural history, and efficacy of treatment of hypophosphatemia in CSHS may improve the care of these patients.

Available only for authorised users

Lim YH et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23(2):397–407CrossRefPubMed

Lim YH, Ovejero D, Derrick KM; Yale Center for Mendelian Genomics, Collins MT, Choate KA (2016) Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J Am Acad Dermatol 75(2):420–427. doi:10.1016/j.jaad.2015.11.012

Aschinberg LC et al (1977) Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions. J Pediatr 91(1):56–60CrossRefPubMed

Dempster DW et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2–17CrossRefPubMedPubMedCentral

Kuznetsov SA et al (1997) Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 12(9):1335–47CrossRefPubMed

Castilla EE, da Graca Dutra M, Orioli-Parreiras IM (1981) Epidemiology of congenital pigmented naevi: I. Incidence rates and relative frequencies. Br J Dermatol 104(3):307–15CrossRefPubMed

Aggarwal S et al (2013) Hypophosphatemic rickets associated with giant hairy nevus. Indian J Endocrinol Metab 17(Suppl 1):S188–90CrossRefPubMedPubMedCentral

Avitan-Hersh E et al (2014) Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23. J Clin Endocrinol Metab 99(1):E132–6CrossRefPubMed

Bouthors J et al (2006) Phacomatosis pigmentokeratotica associated with hypophosphataemic rickets, pheochromocytoma and multiple basal cell carcinomas. Br J Dermatol 155(1):225–6CrossRefPubMed

10.

Cabanillas M et al (2009) Epidermal nevus syndrome associated with polyostotic fibrous dysplasia, CNS lipoma, and aplasia cutis. Dermatol Online J 15(10):7PubMed

11.

Carey DE et al (1986) Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia. J Pediatr 109(6):994–1000CrossRefPubMed

12.

Chou YY et al (2005) Hypophosphatemic rickets associated with epidermal nevus syndrome and giant hairy nevus. J Pediatr Endocrinol Metab 18(1):93–5CrossRefPubMed

13.

de Morais OO et al (2013) Phacomatosis pigmentokeratotica—a patient with hypophosphatemic rickets. Skinmed 11(2):125–8PubMed

14.

Feldmann JL et al (1990) Solomon’s syndrome associated with fibrous dysplasia of bone and vitamin-resistant rickets. Rev Rhum Mal Osteoartic 57(12):881–4PubMed

15.

Gathwala G et al (2013) Giant congenital melanocytic nevi: a rare association with hypophosphatemic rickets. Indian J Pediatr 80(5):430–1CrossRefPubMed

16.

Goldblum JR, Headington JT (1993) Hypophosphatemic vitamin D-resistant rickets and multiple spindle and epithelioid nevi associated with linear nevus sebaceus syndrome. J Am Acad Dermatol 29(1):109–11CrossRefPubMed

17.

Heike CL et al (2005) Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis? Am J Med Genet A 139(2):67–77CrossRef

18.

Hoffman WH et al (2005) Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A 134(3):233–6CrossRefPubMed

19.

Hosalkar HS et al (2003) Linear sebaceous naevus syndrome and resistant rickets. J Bone Joint Surg Br 85(4):578–83CrossRefPubMed

20.

Ivker R, Resnick SD, Skidmore RA (1997) Hypophosphatemic vitamin D-resistant rickets, precocious puberty, and the epidermal nevus syndrome. Arch Dermatol 133(12):1557–61CrossRefPubMed

21.

John M, Shah NS (2005) Hypophosphatemic rickets with epidermal nevus syndrome. Indian Pediatr 42(6):611–2PubMed

22.

Kishida ES et al (2005) Epidermal nevus syndrome associated with adnexal tumors, spitz nevus, and hypophosphatemic vitamin D-resistant rickets. Pediatr Dermatol 22(1):48–54CrossRefPubMed

23.

Klein GL et al (1998) Congenital linear sebaceous nevus syndrome. J Bone Miner Res 13(6):1056–7CrossRefPubMed

24.

Moorjani R, Shaw DG (1976) Feuerstein and Mims syndrome with resistant rickets. Pediatr Radiol 5(2):120–2CrossRefPubMed

25.

Moreira AI et al (2010) Epidermal nevus syndrome associated with hypophosphatemic rickets. Dermatol Online J 16(9):14PubMed

26.

Narazaki R et al (2012) Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23. Pediatr Nephrol 27(5):861–3CrossRefPubMed

27.

Olivares JL et al (1999) Epidermal naevus syndrome and hypophosphataemic rickets: description of a patient with central nervous system anomalies and review of the literature. Eur J Pediatr 158(2):103–7CrossRefPubMed

28.

O’Neill EM (1993) Linear sebaceous naevus syndrome with oncogenic rickets and diffuse pulmonary angiomatosis. J R Soc Med 86(3):177–8PubMedPubMedCentral

29.

Oranje AP et al (1994) Solomon’s epidermal nevus syndrome (type: linear nevus sebaceus) and hypophosphatemic vitamin D-resistant rickets. Arch Dermatol 130(9):1167–71CrossRefPubMed

30.

Pierini AM, Ortonne JP, Floret D (1981) Cutaneous manifestations of McCune-Albright syndrome: report of a case (author’s transl). Ann Dermatol Venereol 108(12):969–76PubMed

31.

Saraswat A et al (2003) Phakomatosis pigmentokeratotica associated with hypophosphataemic vitamin D-resistant rickets: improvement in phosphate homeostasis after partial laser ablation. Br J Dermatol 148(5):1074–6CrossRefPubMed

32.

Sethi SK, Hari P, Bagga A (2010) Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr Nephrol 25(8):1577–8CrossRefPubMed

33.

Shahgholi E et al (2011) Congenital rhabdomyosarcoma, central precocious puberty, hemihypertrophy and hypophosphatemic rickets associated with epidermal nevus syndrome. J Pediatr Endocrinol Metab 24(11–12):1063–6PubMed

34.

Shieh CC, Wang PJ (1991) Giant nevocellular nevi with rickets and brainstem tumor. Pediatr Neurol 7(6):452–4CrossRefPubMed

35.

Skovby F, Svejgaard E, Moller J (1987) Hypophosphatemic rickets in linear sebaceous nevus sequence. J Pediatr 111(6 Pt 1):855–7CrossRefPubMed

36.

Stosiek N et al (1994) Extensive linear epidermal nevus associated with hemangiomas of bones and vitamin-D-resistant rickets. Dermatology 189(3):278–82CrossRefPubMed

37.

Sukkhojaiwaratkul D, Mahachoklertwattana P, Poomthavorn P (2014) Epidermal nevus syndrome with hypophosphatemic rickets in a young girl. J Paediatr Child Health 50(7):566–9CrossRefPubMed

38.

Tokatli A, Coskun T, Ozalp I (1997) Hypophosphatemic vitamin-D resistant rickets associated with epidermal nevus syndrome. A case report. Turk J Pediatr 39(2):247–51PubMed

39.

Vidaurri-de la Cruz H et al (2004) Epidermal nevus syndromes: clinical findings in 35 patients. Pediatr Dermatol 21(4):432–9CrossRefPubMed

40.

Yu AC et al (1995) Epidermal naevus syndrome associated with polyostotic fibrous dysplasia and central precocious puberty. Eur J Pediatr 154(2):102–4CrossRefPubMed

41.

Zutt M et al (2003) Schimmelpenning-Feuerstein-Mims syndrome with hypophosphatemic rickets. Dermatology 207(1):72–6CrossRefPubMed

42.

Rustin MH et al (1989) Polyostotic fibrous dysplasia associated with extensive linear epidermal naevi. Clin Exp Dermatol 14(5):371–5CrossRefPubMed

43.

Bouwes Bavinck JN, van de Kamp JJP (1985) Organoid naevus phakomatosis: Schimmelpenning-Feuerstein-Mims syndrome. Br J Dermatol 113:491–492

44.

Camacho Martinez F, Moreno Gimenez JC (1985) Epidermal nevus syndrome (of Solomon, Fretzin and Dewald). Ann Dermatol Venereol 112(2):143–7PubMed

45.

Grun G, Didier MF (1972) Albright’s syndrome (apropos of 2 cases). Bull Soc Fr Dermatol Syphiligr 79(2):184–5PubMed

46.

Kaplan I, Metzker A, Calderon S (1993) Epidermal nevus syndrome with maxillary involvement. Int J Oral Maxillofac Surg 22(5):298–300CrossRefPubMed

47.

Muhle C et al (1998) Skeletal involvement and follow-up in linear nevus sebaceous syndrome. Eur Radiol 8(4):606–8CrossRefPubMed

48.

Sanmaneechai O, Wisuthsarewong W, Sawathiparnich P (2006) Epidermal nevus syndrome presenting as hypophosphatemic rickets. Endocrinologist 16(3):145–149CrossRef

49.

Sugarman GI, Reed WB (1969) Two unusual neurocutaneous disorders with facial cutaneous signs. Arch Neurol 21(3):242–7CrossRefPubMed

50.

Shpall S et al (1994) Risk of malignant transformation of congenital melanocytic nevi in blacks. Pediatr Dermatol 11(3):204–8CrossRefPubMed

51.

Groesser L et al (2013) Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol 133(8):1998–2003CrossRefPubMed

52.

Groesser L et al (2012) Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 44(7):783–U211CrossRefPubMed

53.

Hafner C et al (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 49(4):249–253CrossRefPubMed

54.

Kinsler VA et al (2013) Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Investig Dermatol 133(9):2229–2236CrossRefPubMedPubMedCentral

55.

Boyce AM, Collins MT (1993) Fibrous dysplasia/McCune-Albright syndrome. In: Pagon RA et al (ed) GeneReviews(R). Seattle (WA)

56.

Lorenz-Depiereux B et al (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38(11):1248–50CrossRefPubMed

57.

Geller JL et al (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22(6):931–7CrossRefPubMed

58.

Carpenter TO et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124(4):1587–97CrossRefPubMedPubMedCentral

59.

Wohrle S et al (2013) Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28(4):899–911CrossRefPubMed

60.

Boyce AM, Bhattacharyya N, Collins MT (2013) Fibrous dysplasia and fibroblast growth factor-23 regulation. Curr Osteoporos Rep 11(2):65–71CrossRefPubMedPubMedCentral

61.

Kuznetsov SA et al (2008) Age-dependent demise of GNAS-mutated skeletal stem cells and “normalization” of fibrous dysplasia of bone. J Bone Miner Res 23(11):1731–40CrossRefPubMedPubMedCentral

62.

Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192(4):547–56CrossRefPubMedPubMedCentral

63.

Paller AS et al (1994) Genetic and clinical mosaicism in a type of epidermal nevus. N Engl J Med 331(21):1408–15CrossRefPubMed

64.

Chantorn R, Shwayder T (2011) Phacomatosis pigmentokeratotica: a further case without extracutaneous anomalies and review of the condition. Pediatr Dermatol 28(6):715–9CrossRefPubMed

65.

Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–30CrossRefPubMed

Title: Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment
Authors: D. Ovejero
Y. H. Lim
A. M. Boyce
R. I. Gafni
E. McCarthy
T. A. Nguyen
L. F. Eichenfield
C. M. C. DeKlotz
L. C. Guthrie
L. L. Tosi
P. S. Thornton
K. A. Choate
M. T. Collins
Publication date: 01-12-2016
Publisher: Springer London
Published in: Osteoporosis International / Issue 12/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-016-3702-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment

Abstract

Summary

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2016

Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome

Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes

Predictors of bone mineral density testing among older women on Medicare

Visceral fat measured by DXA is associated with increased risk of non-spine fractures in nonobese elderly women: a population-based prospective cohort analysis from the São Paulo Ageing & Health (SPAH) Study

Health-related quality of life in older people with osteoporotic vertebral fractures: response to comments by Sani et al.

Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial